Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus SODIUM CHLORIDE 0 9 AND POTASSIUM CHLORIDE 0 22 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus SODIUM CHLORIDE 0 9 AND POTASSIUM CHLORIDE 0 22 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE IN PLASTIC CONTAINER vs SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Sodium chloride (0.9%) provides isotonic concentration of sodium and chloride ions to maintain extracellular fluid volume and osmolarity. Potassium chloride (0.22%) provides potassium ions essential for nerve conduction, muscle contraction, and acid-base balance.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
Intravenous infusion; typical adult dose is 1-2 L over 24 hours, titrated to fluid and electrolyte needs. Maximum rate 1 L/hour under controlled conditions.
None Documented
None Documented
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Not applicable (endogenous substances); distribution half-life ~1–2 hours for infused dose; clinical context: no true elimination half-life due to homeostatic regulation; steady-state achieved with continuous infusion.
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Renal: Sodium >95% (glomerular filtration and variable tubular reabsorption); Potassium >90% (glomerular filtration and tubular secretion/reabsorption). Fecal <5%.
Category C
Category A/B
Electrolyte
Electrolyte